News Archives - Page 7 of 49 - Telix Pharmaceuticals

Telix at ANZSNM Annual Scientific Meeting 2025

Telix Responds to Recent U.S. Government Actions- Most Favored Nation

Telix advises that it has evaluated the Executive Order issued by the United States (U.S.) Government to implement a “Most-Favored Nation” (MFN) policy around drug pricing. Based on currently available...

Illuccix China Phase 3 Study Completes Enrolment

Clinical, News,

Telix today announces that that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Chinese patients has completed patient...

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

News,

Telix today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging...

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic

News,

Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in the Czech Republic by the...